{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:23:32Z","timestamp":1792859012705,"version":"4.5.0"},"reference-count":91,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/14787210.2024.2362911","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T09:56:34Z","timestamp":1717667794000},"page":"399-412","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Mediprobe Research Inc., London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, Ontario, Canada"},{"name":"School of Pharmacy, BRAC University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Shemer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Galili","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15999"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80215-0"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890450124022"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107754"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16394"},{"issue":"10","key":"e_1_3_7_9_1","first-page":"29","article-title":"ONYCHOMYCOSIS: a review of new and emerging topical and device-based treatments","volume":"12","author":"Kawa N","year":"2019","unstructured":"Kawa N, Lee KC, Anderson RR, et al. ONYCHOMYCOSIS: a review of new and emerging topical and device-based treatments. J Clin Aesthet Dermatol. 2019 Oct;12(10):29\u201334.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_7_10_1","unstructured":"Penlac\u00ae Nail Lacquer (ciclopirox) Topical Solution 8%. 2004 [cited 2024 Feb 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf"},{"key":"e_1_3_7_11_1","unstructured":"US FDA. Highlights of prescribing information JUBLIA\u00ae (efinaconazole) topical solution. 2022 [cited 2024 Feb 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203567s010lbl.pdf"},{"key":"e_1_3_7_12_1","unstructured":"US FDA. Highlights of prescribing information KERYDIN\u00ae (tavaborole) topical solution. 2018 [cited 2024 Feb 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204427s006lbl.pdf"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00660-1"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70275-5"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540100500303"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780410001731583"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855050-00004"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19217"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2305304"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00917-8"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2280137"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13091"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.02.016"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof8030220"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00056-21"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13393"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-019-4431-7"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040207"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2019.100903"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-17"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2455"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13411"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01498-1"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040195"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof7060419"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.025"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijm.v14i6.11269"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S246025"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0572"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3317-4"},{"key":"e_1_3_7_41_1","first-page":"1","article-title":"An update on antifungal resistance in dermatophytosis","volume":"17","author":"Gupta AK","year":"2024","unstructured":"Gupta AK, Mann A, Polla Ravi S, et al. An update on antifungal resistance in dermatophytosis. Expert Opin Pharmacother. 2024 Apr;17:1\u20139.","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.10.010"},{"key":"e_1_3_7_43_1","unstructured":"US FDA. Highlights of prescribing information VFEND\u00ae (voriconazole). 2022 [cited 2024 Feb 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021266s053 021267s063 021630s042lbl.pdf"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000276"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt229"},{"key":"e_1_3_7_46_1","unstructured":"US FDA. Highlights of prescribing information Noxafil\u00ae (posaconazole). 2021 [cited 2024 Fer 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022003s018s020 0205053s002s004 0205596s001s003lbl.pdf"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01616-09"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01306-y"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319340-000000000-00000"},{"key":"e_1_3_7_50_1","first-page":"2876","volume-title":"Kucers\u2019 the use of antibiotics","author":"Ramos-Mart\u00edn V","year":"2017","unstructured":"Ramos-Mart\u00edn V, Ling LM, Slavin MR. Ravuconazole. Kucers\u2019 the use of antibiotics. Florida, USA: CRC Press; 2017. p. 2876\u20132882."},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.153.79"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2021-0173"},{"key":"e_1_3_7_53_1","unstructured":"US FDA. Highlights of prescribing information VIVJOA\u2122 (oteseconazole) capsules for oral use. 2022 [cited 2024 Feb 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000lbl.pdf"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2019.103254"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44259-023-00007-2"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci100403b"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00811-6"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269721"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01291-18"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780400029114"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008819"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S420580"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103953"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645070-00002"},{"key":"e_1_3_7_65_1","first-page":"2823","volume-title":"Kucers\u2019 the use of antibiotics","author":"Neely M","year":"2017","unstructured":"Neely M, Neofytos DV. Voriconazole. Kucers\u2019 the use of antibiotics. Florida, USA: CRC Press; 2017. p. 2823\u20132842."},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5040066"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2788-2795.2003"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13517"},{"issue":"2","key":"e_1_3_7_69_1","first-page":"24","article-title":"Efficacy and safety of voriconazole in the treatment failure cases of","volume":"27","author":"Khondker L","year":"2020","unstructured":"Khondker L. Efficacy and safety of voriconazole in the treatment failure cases of Gulf J Dermatol And Venereology. 2020;27(2):24\u201330.","journal-title":"Gulf J Dermatol And Venereology"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2022.101306"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2011.1616"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19420"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10660.x"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2154"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14607"},{"key":"e_1_3_7_76_1","unstructured":"Kusuri-no-Shiori (Drug information sheet) on NAILIN Capsules 100mg. Eisai Co. Ltd; [cited 2024 Feb 21]. Available from: https:\/\/www.rad-ar.or.jp\/siori\/english\/kekka.cgi?n=40304#"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01212.x"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19224"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13683"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.23.07694-6"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15495"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa394"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v41is4a03"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy290"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01288-4"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks256"},{"key":"e_1_3_7_87_1","unstructured":"Stone S. Antifungals: treatment chart (RxFiles). 2021 [cited 2024 Jan 2]. Available from: https:\/\/www.rxfiles.ca\/RxFiles\/uploads\/documents\/members\/cht-antifungal.pdf"},{"key":"e_1_3_7_88_1","unstructured":"US FDA. SPORANOX\u00ae(itraconazole) capsules. 2019 [cited 2024 Feb 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020083s063lbl.pdf"},{"key":"e_1_3_7_89_1","unstructured":"US FDA. Highlights of prescribing information LAMISIL (terbinafine hydrochloride) tablets for oral use. 2019 [cited 2024 Feb 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020539s033lbl.pdf"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.703308"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2015.1020544"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27628"},{"key":"e_1_3_7_93_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.655327"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2024.2362911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:56:55Z","timestamp":1727186215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2024.2362911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/14787210.2024.2362911"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2024.2362911","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}